Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Trastuzumab PET in Breast Cancer
NCT02065609Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2014
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-trastuzumab (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Number of Participants With Adverse Events at 30 Days. Started Feb 2014; status: completed.
02
Drugs
89Zr-trastuzumab
Beyond the preview
Go deeper on NCT02065609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065609.